Literature DB >> 10700419

Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group.

.   

Abstract

BACKGROUND AND
OBJECTIVE: Human papillomavirus (HPV) infections appear to be central to the development of cervical cancer. This study addresses the question of whether testing women who have low-grade squamous intraepithelial lesions (LSILs) of the uterine cervix for HPV DNA is useful as a triage strategy.
METHODS: Four clinical centers in different areas of the United States participated in a randomized clinical trial of the use of HPV DNA testing in women with cytologic evidence of atypical squamous cells of undetermined significance (ASCUS) or LSIL. The study sample in this article consists only of women who had LSIL at enrollment. Within 6 months of an LSIL diagnosis (based on a Pap smear read by a community-based cytopathologist), women who were 18 years of age or older completed a standardized questionnaire and underwent a pelvic examination that included collection of cervical specimens for HPV DNA testing by Hybrid Capture II (HCII)(R) assay.
RESULTS: Among the 642 women referred with LSIL who had analyzable test results, the mean chronologic age and age at first coitus were similar among the four clinical centers, despite the centers' ethnic and geographic diversity. Overall, HPV DNA was detected in cervical samples from 532 (82.9%) of the 642 women (95% confidence interval = 79.7%-85.7%). This high frequency of HPV positivity was confirmed by polymerase chain reaction (PCR) assays in a subset of 210 paired specimens tested by HCII and PCR (81.4% were positive by both methods).
CONCLUSION: Because a very high percentage of women with an LSIL diagnosis from Pap smears are positive for HPV DNA by HCII testing, there is limited potential for this assay to direct decisions about the clinical management of women with LSIL. The role of HPV testing in the management of women with ASCUS is still under study.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10700419     DOI: 10.1093/jnci/92.5.397

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  74 in total

1.  HPV testing for clarifying borderline cervical smear results.

Authors:  M M Manos
Journal:  BMJ       Date:  2001-04-14

2.  Human papillomavirus testing and the management of women with mildly abnormal cervical smears: an observational study.

Authors:  G Rebello; N Hallam; G Smart; D Farquharson; J McCafferty
Journal:  BMJ       Date:  2001-04-14

3.  Human papillomavirus testing. Authors' comments.

Authors:  G Rebello; N Hallam; G Smart; D Farquharson; J McCafferty
Journal:  BMJ       Date:  2001-07-14

4.  Screening for cervical cancer: should we test for infection with high-risk HPV?

Authors:  C J Meijer; P J Snijders; A J van den Brule
Journal:  CMAJ       Date:  2000-09-05       Impact factor: 8.262

5.  Evaluation of a new DNA test for detection of carcinogenic human papillomavirus.

Authors:  Philip E Castle; Erin C Gutierrez; Sharon V Leitch; Courtney E Maus; Ray A McMillian; William A Nussbaumer; Laurence M Vaughan; Cosette M Wheeler; Patti E Gravitt; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2011-06-01       Impact factor: 5.948

6.  Policy implications of adjusting randomized trial data for economic evaluations: a demonstration from the ASCUS-LSIL Triage Study.

Authors:  Nicole G Campos; Philip E Castle; Mark Schiffman; Jane J Kim
Journal:  Med Decis Making       Date:  2011-12-06       Impact factor: 2.583

Review 7.  Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts.

Authors:  Vikrant V Sahasrabuddhe; Patricia Luhn; Nicolas Wentzensen
Journal:  Future Microbiol       Date:  2011-09       Impact factor: 3.165

8.  Impact of improved classification on the association of human papillomavirus with cervical precancer.

Authors:  Philip E Castle; Mark Schiffman; Cosette M Wheeler; Nicolas Wentzensen; Patti E Gravitt
Journal:  Am J Epidemiol       Date:  2009-12-10       Impact factor: 4.897

9.  Invited commentary: Human papillomavirus infection and risk of cervical precancer--using the right methods to answer the right questions.

Authors:  Eduardo L Franco; Joseph Tota
Journal:  Am J Epidemiol       Date:  2009-12-10       Impact factor: 4.897

10.  Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study.

Authors:  Philip E Castle; Patti E Gravitt; Diane Solomon; Cosette M Wheeler; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2007-11-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.